Pentraxin-3 in Hysterectomy Patients

Comparison of the Tissue Trauma Markers Following Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04366375

Enrollment

Registered

2020-04-28

Start date

2015-01-13

Completion date

2015-12-07

Last updated

2020-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Hysterectomy, Laparoscopic Hysterectomy

Keywords

Pentraxin-3, tissue trauma, hysterectomy, neutrophil to lymphocyte ratio

Brief summary

Comparison of the Tissue Trauma Markers Following Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy

Detailed description

Acute trauma and major surgeries activate a series of cascades to evoke systemic inflammatory response. The magnitude of the resulting inflammatory response is proportional to the severity of the tissue trauma. Abdominal or laparoscopic technique is widely used for the purpose of hysterectomy surgery. It is crucial for many aspects to compare these two techniques of hysterectomy in terms of the surgery-induced trauma. In this study, the severity of the inflammatory response resulting from the tissue trauma due to the techniques of TLH+BSO and TAH+BSO applied in our department were compared based on the PTX-3 molecule.

Interventions

DIAGNOSTIC_TESTPTX-3

Pentraxin-3 ng/mL PTX-3 levels were measured using human PTX3 ELISA Kit 96 Tests/Box (Cat. No: CK-E90303) (Hangzhou Eastbiopharm Co.,Ltd., PRC) read by a ELISA device matching with the kit. For the purpose of measurement, microplate washer RT 2600 device and Rayto microplate reader RT 2100C device were used.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

·TLH+BSO patients and TAH+BSO patients

Exclusion criteria

* History of a chronic disease (coronary artery disease, diabetes mellitus, hypertension, coronary liver failures, chronic kidney disease, chronic respiratory diseases, connective tissue disorders) which may affect levels of PTX-3 and other inflammatory markers. * Prior surgery due to malignancy. * History of an intra-abdominal surgery, except for cesarean section. * History of any disease which may lead to intra-abdominal adhesions (endometriosis, past pelvic infection).

Design outcomes

Primary

Measure	Time frame	Description
Pentraxin-3 level	Before 24 hours preoperatively and upto 24 hours postoperatively	Pentraxin-3 ng/mL

Secondary

Measure	Time frame	Description
(NLR)	Up to 24 hours postoperative	neutrophile/lymphocyte ratio

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026